About the Company
Immunomedics, Inc. researching, developing, manufacturing, and marketing biopharmaceutical products. It focuses on monoclonal antibody-based products for the targeted treatment of cancer. The company was founded by David M. Goldenberg in July 1982 and is headquartered in Morris Plains, NJ.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $IMMU News
Gilead Sciences Inc's Dividend Analysis
Gilead Sciences Inc (NASDAQ:GILD) recently announced a dividend of $0.77 per share, payable on 2024-03-28, with the ...
Gilead bets on ‘trispecifics’ in latest cancer drug deal
A small partnership with Merus adds to Gilead’s string of cancer dealmaking, which, so far, has not paid off for the large biotech.
Loading the latest forecasts...